This page contains links to a selection of notices sent to the public and media outlets that were written by members of the FLCCC team.
July 16, 2021 | Press Release
Statement by the FLCCC & BiRD groups on the retraction of early research on Ivermectin: The Remaining Data Continue to Prove Ivermectin Effective in Preventing and Treating COVID-19.
WASHINGTON, D.C. and BATH, SOMERSET, U.K. – The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars,
and the British Ivermectin Recommendation Development Group (BIRD), a U.K. based group… Read full statement
July 1, 2021 | Joint Statement
Joint Statement of the FLCCC & the BiRD Group on the Unethical and Questionable Methods of the Upcoming PRINCIPLE Trial.
June 23, 2021 | Press Release
Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial
From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings. Led by the University of Oxford, PRINCIPLE is investigating treatments for people at more risk of serious illness from COVID-19 which can speed up recovery, reduce the severity of symptoms and prevent the need for hospital admission. To find out more about the study, visit www.principletrial.org
June 14, 2021 | Public Statement
Dr. Kory on the U.S. Deal to Give 1.2 Billion Taxpayer Dollars to Merck for New Drug Instead of Distributing Safe, Effective, Inexpensive Ivermectin.
Also download Statement Transcript
May 3, 2021 | Joint Statement
Joint Statement on Widespread Use of Ivermectin in India for Prevention and Early Treatment
The Evidence-Based Medicine Consultancy Ltd (E-BMC Ltd) is a UK-based independent medical research company that contributes to the quality of healthcare globally through the rigorous evaluation of medical evidence to support clinical practice guidelines. Read Full Statement
April 29, 2021 | Public Statement
Front Line COVID-19 Critical Care Alliance Statement on New Guidance on Ivermectin from the All India Institute of Medical Science
WASHINGTON, D.C. – The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars, today praised the recent updated guidance from the All India Institute of Medical Science (AIIMS) to include ivermectin in its guidelines for the treatment of COVID-19. Read full statement
April 9, 2021 | Press Release
Front Line COVID-19 Critical Care Alliance Statement on Recent Washington Post Story
WASHINGTON, D.C. – We appreciate the interest from the Washington Post in the use of ivermectin as a safe and effective preventative and treatment for COVID-19. However, the article published yesterday left out several key components of the complete story of how ivermectin is saving lives all over the world. These include the overwhelming amount of data on ivermectin… Read full release
March 31, 2021 | Public Statement
FLCCC Alliance Statement on Weak Guidance on Ivermectin from the World Health Organization
WHO ignores significant data, including several large clinical trials, while claiming insufficient evidence to recommend the use of ivermectin to prevent and treat COVID-19.
March 18, 2021 | Press Release (on EIN Presswire)
Leading Experts Discuss the Latest Research on Preventing & Treating COVID-19 with Ivermectin and Call for its Immediate Global Use to End the Pandemic
A group of medical and scientific experts convened by the Front Line COVID-19 Critical Care Alliance (FLCCC) today call for action to put an end to the COVID-19 pandemic by immediately adopting policies that allow for the use of ivermectin in the prevention and treatment of COVID-19.
March 9, 2021 | Press Release
FLCCC Alliance Applauds International Group of Medical Experts’ Recognition of Ivermectin as a Safe and Effective Treatment for COVID-19
UK-based panel of leading experts publish their review of the latest research and call for the immediate global adoption of ivermectin to prevent and treat COVID-19 – e-bmc.co.uk.
March 7, 2021 | Public Statement
FLCCC Alliance Statement on Misleading FDA Guidance on Ivermectin
The FLCCC Alliance is troubled by the recently updated consumer guidance on Ivermectin from the FDA. The guidance from the FDA is misleading and has the potential to raise unwarranted concern over an important drug in the prevention and treatment of COVID-19.
Feb 28, 2021 | Public Statement
FLCCC Alliance Response to the N.I.H. Guideline Committee Recommendation on Ivermectin use in COVID-19 dated February 11, 2021
Feb 7, 2021 | Public Statement
FLCCC Alliance Response to Merck’s Public Statements on Efficacy of Ivermectin in COVID-19
Merck’s assessments of ivermectin’s efficacy in COVID-19 are in striking contrast with the findings reported by multiple expert group’s systematic reviews from across the globe, including metaanalyses of the updated scientific literature […]
Feb 5, 2021 | Public Statement
FLCCC Alliance Response to Dr. Kory’s Senate Testimony Removed by YouTube
YouTube removed the video link of Dr. Pierre Kory’s sworn testimony to the Senate Committee on Homeland Security and Governmental Affairs on official United States business […]
Jan 24, 2021 | Public Statement
FLCCC Alliance Open Letter to the Investigators of the Oxford PRINCIPLE Trial on Ivermectin in COVID‑19
The FLCCC Alliance wishes to raise concerns about the proposed design of the Oxford PRINCIPLE Trial of ivermectin in COVID-19. We believe that it is an ethical imperative to provide those considering participation a truthful account of the available evidence of ivermectin’s efficacy in COVID-19 […
Jan 17, 2021 | Public Statement
FLCCC Alliance Response to the NIH Guideline Committee Recommendation on Ivermectin use in COVID-19 dated January 14th, 2021
The FLCCC considers the Panel’s unwillingness to provide more specific guidance in support of the use of ivermectin in COVID-19 to be severely out of alignment with the known clinical, epidemiological, and observational data. Our detailed response to the Panel’s criticism of the existing evidence base […]
Jan 15, 2021 | Press Release
Ivermectin is Now a Treatment Option for Health Care Providers
NIH (National Institutes of Health) Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Jan 7, 2021 | Press Release
FLCCC Alliance Invited to the NIH COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin
On January 6, 2021, our Drs. Pierre Kory and Paul Marik, founding members of the FLCCC Alliance, appeared before the National Institutes of Health COVID-19 Treatment Guidelines Panel to urge review of current data and an updated NIH guidance.
Dec 22, 2020 | Press Release
New One-page Summary of the Review on Ivermectin in COVID-19
FLCCC Alliance one-page summary of clinical trials showing large magnitude improvements in COVID-19 patients treated with Ivermectin. Related files:
Review on ivermectin in the prophylaxis and treatment of COVID-19 — One-page Summary of the Review
Please also see our FAQ on Ivermectin in the Treatment of COVID-19
Dec 16, 2020 | Press Release
MATH+ Hospital Treatment Protocol for COVID-19 Now Published (JIC)
FLCCC Alliance peer-reviewed paper published in the Journal of Intensive Care Medicine. This protocol potentially offers a life-saving approach to the management of hospitalized COVID-19 patients.
Dec 8, 2020 | Press Release
Dr. Kory Testifies to Senate Committee About I-MASK+
Dr. Pierre Kory, President of the FLCCC Alliance addresses the Senate Committee on Homeland Security and Governmental Affairs looking into earlyoutpatient COVID-19 treatment.
Watch the video on our Official Testimony page
Dec 4, 2020 | Press Release
FLCCC Alliance Press Conference on Ivermectin & COVID-19 in Houston, Texas and Follow-Up Press Release
FLCCC Alliance calls on national health authorities to immediately review medical evidence showing the efficacy of ivermectin for the prevention of COVID-19 and as an early outpatient treatment.
Video documentation and additional material: Electronic Press Kit for the News Conference on Dec 4, 2020